Once described as obesity medicines for ‘patients,’ GLP-1s are increasingly lifestyle drugs for ‘customers’ Novo Nordisk, a pioneer in the field, has leaned hard into the shift

https://www.statnews.com/2026/09/28/glp1-marketing-shift-obesity-medicine-weight-loss-drug/?utm_campaign=morning_rounds&utm_medium=email&_hsenc=p2ANqtz--vZmTMF5QLZYAeSl9E4nyjDt7xqcBIMBFNQJWHVYcf1OvdcOgnazgl954apBYr8qMrHDape2MUERguqJXBEdDhnGxNFQ&_hsmi=441235571&utm_content=441235571&utm_source=hs_email By Elaine ChenSept. 28, 2026 Chen, a national biotech reporter, is the co-author of The Readout, a newsletter about the business, science, and politics of biotech. “Live lighter” and “summer glow up” sound like magazine cover taglines. They are also, it turns out, slogans Novo Nordisk has used to promote its GLP-1s. STAT’s Elaine Chen has taken note of the way Novo and other companies have reframed their marketing of these important medications. “Once promoted as tools to address obesity as a medical issue, GLP-1 drugs are increasingly being seen — and marketed — as a way to look and feel better generally,” she writes. Why are they making this shift? Elaine unravels that mystery, weaving together the way insurance companies’ coverage decisions have shaped how these medicines are used.